We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-2.03%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$380M
(-13%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-8.45%
Top 10 Holdings %
Top 10 Hldgs %
29.58%
Holding
106
New
13
Increased
24
Reduced
44
Closed
23
Top Buys
| 1 |
Boston Scientific
BSX
|
+$67.1M |
| 2 |
Cigna
CI
|
+$59.2M |
| 3 |
UnitedHealth
UNH
|
+$55.2M |
| 4 |
Humana
HUM
|
+$51.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$46.7M |
Top Sells
| 1 |
GE HealthCare
GEHC
|
+$84.9M |
| 2 |
AbbVie
ABBV
|
+$69.8M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$57.9M |
| 4 |
Cencora
COR
|
+$57.7M |
| 5 |
argenx
ARGX
|
+$50.7M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Boston Scientific
BSX
$67B
| $109M | 4.39% |
2,065,800
+1,280,100
| +163% | +$67.1M |
|
2
Jazz Pharmaceuticals
JAZZ
$15.1B
| $103M | 4.16% |
797,500
+94,722
| +13% | +$12.6M |
|
3
Becton Dickinson
BDX
$43.7B
| $74.1M | 2.99% |
286,800
-111,250
| -28% | -$30.1M |
|
4
Neurocrine Biosciences
NBIX
$17.3B
| $73.4M | 2.95% |
652,100
-13,216
| -2% | -$1.39M |
|
5
McKesson
MCK
$95.2B
| $72.3M | 2.91% |
166,300
+65,100
| +64% | +$27.4M |
|
6
Legend Biotech
LEGN
$4.33B
| $65M | 2.62% |
967,000
+168,100
| +21% | +$11.7M |
|
7
Tenet Healthcare
THC
$17.2B
| $63.5M | 2.56% |
963,800
-26,700
| -3% | -$2M |
|
|
8
Cigna
CI
$75.5B
| $59.4M | 2.39% |
+207,700
| New | +$59.2M |
|
9
IDEAYA Biosciences
IDYA
$3.52B
| $57.9M | 2.33% |
2,144,971
-840,729
| -28% | -$21.3M |
|
|
10
UnitedHealth
UNH
$413B
| $56.6M | 2.28% |
+112,200
| New | +$55.2M |
|
11
Sarepta Therapeutics
SRPT
$1.83B
| $54.5M | 2.2% |
450,000
+152,500
| +51% | +$17.2M |
|
|
12
Humana
HUM
$49.8B
| $53.7M | 2.16% |
+110,300
| New | +$51.8M |
|
13
Arvinas
ARVN
$532M
| $51.4M | 2.07% |
2,614,960
-158,229
| -6% | -$3.88M |
|
14
Acadia Healthcare
ACHC
$3.05B
| $50.3M | 2.02% |
715,000
+165,000
| +30% | +$12.3M |
|
|
KRTX
15
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $48.5M | 1.95% |
286,700
-155,500
| -35% | -$29.2M |
|
16
Regeneron Pharmaceuticals
REGN
$70.2B
| $47.7M | 1.92% |
58,000
+33,200
| +134% | +$26.1M |
|
17
Zoetis
ZTS
$32B
| $45.6M | 1.84% |
262,100
+45,100
| +21% | +$8.19M |
|
18
Immunovant
IMVT
$8.04B
| $45.1M | 1.81% |
1,173,662
-911,338
| -44% | -$20.6M |
|
19
MoonLake Immunotherapeutics
MLTX
$1.64B
| $44.3M | 1.78% |
777,172
+377,172
| +94% | +$20.8M |
|
20
Danaher
DHR
$143B
| $43.8M | 1.76% |
+199,205
| New | +$44.4M |
|
21
Zentalis Pharmaceuticals
ZNTL
$332M
| $42.1M | 1.7% |
2,100,000
-234,000
| -10% | -$5.94M |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $41.7M | 1.68% |
+801,100
| New | +$46.7M |
|
23
Syndax Pharmaceuticals
SNDX
$2.12B
| $41M | 1.65% |
2,821,000
-51,000
| -2% | -$965K |
|
24
Eli Lilly
LLY
$1.03T
| $40.3M | 1.62% |
75,000
-58,000
| -44% | -$29.9M |
|
25
Natera
NTRA
$39.9B
| $39.8M | 1.6% |
899,000
+466,100
| +108% | +$23.8M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH